CAS: 65002-17-7; (R)-3-Mercapto-2-(2-Mercapto-2-Methylpropanamido)Propanoic Acid

该化合物是一种合成化合物,主要用于治疗风湿性关节炎,主要用作疾病调控抗血性药物(DARD),被归类为含有硫醇的化合物,通过调制免疫反应和表现出抗炎特性,有助于其行动机制.胺因其能够减少与自免疫条件有关的联合炎和损害而闻名.该物质分子重量相对较低,在水中可溶解,有利于吸收和在体内生物利用.其化学结构包括一种二硫醇细胞,这对它的再活性和治疗效果意义重大.胺一般具有良好的耐受性,但与任何药物一样,可能具有副作用,包括胃肠扰动和潜在的肝脏毒性.在治疗期间,监测对于管理任何不良反应至关重要.

结构式图片

上下游产品

S-benzyl-N-(S-benzyl-2-mercapto-2-methylpropanoyl)-L-cysteine L-Cysteine 2-mercapto-2-methylpropanoic acid2-methylmercapto-isobutyroyl-l-S-methylcysteine (4R)-tetrahydro-7,7-dimethyl-6-oxo-3H-1,2,5-dithiazepine-4-carboxylic acid

合成工艺路线路线简述

    S-Benzyl-N-(S-Benzyl-2-Mercapto-2-Methylpropanoyl)-L-Cysteine置于氨,Sodium体系中,用81%的收率获得产物布溪那明
    参考文献:Thiol Compounds. Ii. Synthesis And Antihypertensive Activity Of Mercaptoacylamino Acids.
    标题:Thiol Compounds. Ii. Synthesis And Antihypertensive Activity Of Mercaptoacylamino Acids.
    摘要:本文描述了一系列巯基氨基酸的合成和结构-活性关系.对这些化合物进行了抗高血压活性测试.在将这些化合物作为血管紧张素 I 转换酶抑制剂进行体外筛选时,发现 N-(2-巯基丙酰基)-L-半胱氨酸-A(7A)和 N2-(2-巯基丙酰基)-L-色氨酸-A(20A)的活性分别是硫普罗宁的 10 倍和 20 倍.
    DOI:10.1248/cpb.29.940

    海关参考信息

    专利信息


    专利号:CN-1425662-A
    优先权日:2002-12-23
    标题:Synthesis of new intermediate 5,5-dimethyl-2-thione-4-one-1-thio-3-oxo-oxolane in the synthesis of Bucillamine

    专利号:US-11993606-B2
    优先权日:2015-10-16
    标题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; PANGAN AILEEN L; SONG IN-HO; KLÜNDER BEN; VOSS JEFFREY W; PADLEY ROBERT J; CAMP HEIDI S
    权利人:ABBVIE INC
    摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

    专利号:US-11512092-B2
    优先权日:2015-10-16
    标题 :Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    发明人:ALLIAN AYMAN; JAYANTH JAYANTHY; MOHAMED MOHAMED-ESLAM F; MULHERN MATHEW; NORDSTROM FREDRIK LARS; OTHMAN AHMED A; ROZEMA MICHAEL J; BHAGAVATULA LAKSHMI; MARROUM PATRICK J; MAYER PETER T; SHEIKH AHMAD Y; BORCHARDT THOMAS B; KLÜNDER BEN
    权利人:ABBVIE INC
    摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

    专利号:US-11524964-B2
    优先权日:2015-10-16
    标题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; KLÜNDER BEN; PANGAN AILEEN L; SONG IN-HO
    权利人:ABBVIE INC
    摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

    专利号:US-11993605-B2
    优先权日:2015-10-16
    标 题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; KLÜNDER BEN; PANGAN AILEEN L; ANDERSON JACLYN KAY; VOSS JEFFREY W; PADLEY ROBERT J; CAMP HEIDI S
    权利人:ABBVIE INC
    摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.

    专利号:CN-101260101-B
    优先权日:2007-03-09
    标题:Synthesis of intermediate 5,5-dimethyl-1,3-one-2,4-thiolane of bucillamine
    盐城云涛化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yuntao-chem.com
    企业联系电话:0515-83090980;13512592619👤
    📞盐城云涛化工有限公司 ⚠️参考联系方式
    联系人:郭先生 13512592619
    电话:0515-83090980;13512592619
    手机:13512592619
    传真:0515-83090980
    邮箱:2838893166@qq.com
    通信地址: 江苏省盐城市解放南路239号汇景大厦613室
    邮编: 224011
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省盐城市解放南路239号汇景大厦613室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Horwitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev. 2003 Summer;21(2):77-90. doi: 10.1111/j.1527-3466.2003.tb00107.x. 19(3):111-112. doi: 10.1002/jgf2.169.
    3: Yanagishita T, Tamada Y, Watanabe D. Bucillamine-induced pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1242-3. doi: 10.1111/jdv.12472. Epub 2014 Mar 18. 4(1):122-125. doi: 10.1080/24725625.2019.1673939. Epub 2019 Oct 14. 33(3):793-7. doi: 10.1007/s00296-011-2241-z. Epub 2011 Nov 17. Erratum in: Rheumatol Int. 2013 Oct;33(10):2707. Kawashima, Hironori [corrected to Hirotoshi, Kawashima]. 96(4):870-876. doi: 10.1111/php.13228. Epub 2020 Apr 13.
    7: Frank M. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank. Future Microbiol. 2022 Feb;17(3):157-159. doi: 10.2217/fmb-2021-0277. Epub 2022 Jan 19.

    合成参考文献


    参考文献:10.4137/ccrep.s5514
    摘要:Isozaki T, Yajima N, Sato M, Takahashi R, Wakabayashi K, Miwa Y, Negishi M, Ide H, Kasama T. A case of rheumatoid arthritis with bucillamine-induced yellow nail syndrome initially manifesting as pulmonary disease. Clin Med Insights Case Rep. 2010;3():63–8.
    参考文献:10.1007/s10067-011-1810-6
    摘要:Ogasawara M, Tamura N, Kageyama M, Onuma S, Kusaoi M, Toyama S, Sekiya F, Matsudaira R, Nawata M, Tada K, Matsushita M, Kempe K, Amano H, Morimoto S, Yamaji K, Takasaki Y. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clin Rheumatol. 2012 Feb;31(2):251–7. doi: 10.1007/s10067-011-1810-6.
    参考文献:10.1007/s00296-011-1989-5
    摘要:Choe JY, Lee H, Jung HY, Park SH, Bae SC, Kim SK. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012 Jun;32(6):1837–42. doi: 10.1007/s00296-011-1989-5.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知